SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Giovannoni, G
Right arrow Articles by Thompson, E J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giovannoni, G
Right arrow Articles by Thompson, E J
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Are there any body fluid markers of brain atrophy in multiple sclerosis?

G Giovannoni

Departments of Clinical Neurology and Neurochemistry, Institute of Neurology, Queen Square, London WC1N 3BG, UK

A JE Green

Departments of Clinical Neurology and Neurochemistry, Institute of Neurology, Queen Square, London WC1N 3BG, UK

E J Thompson

Departments of Clinical Neurology and Neurochemistry, Institute of Neurology, Queen Square, London WC1N 3BG, UK

The weak correlation between inflammatory activity and disease progression in patients with multiple sclerosis has shifted the emphasis from inflammatory monitoring to the investigation of the pathological processes of demyelination, axonal loss, and gliosis. New magnetic resonance imaging (MRI) techniques that have been developed to measure these processes appear very promising. This paper will briefly discuss potential body fluid markers of axonal loss, gliosis and demyelination, as the pathological substrates of brain atrophy, their function and the principles behind their future study in patients with multiple sclerosis.

Key Words: multiple sclerosis • urine • neopterin

Multiple Sclerosis, Vol. 4, No. 3, 138-142 (1998)
DOI: 10.1177/135245859800400310
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 BrainHome page
B. Bielekova and R. Martin
Development of biomarkers in multiple sclerosis
Brain, July 1, 2004; 127(7): 1463 - 1478.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. Martinez-Yelamos, A. Saiz, R. Sanchez-Valle, V. Casado, J. M. Ramon, F. Graus, and T. Arbizu
14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis
Neurology, August 28, 2001; 57(4): 722 - 724.
[Abstract] [Full Text] [PDF]


Advertisement